# A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers

> **NCT00755638** · PHASE1 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 48 (actual)

## Conditions studied

- Muscle Loss

## Interventions

- **BIOLOGICAL:** ACE-031

## Key facts

- **NCT ID:** NCT00755638
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2009-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755638, "A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00755638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*